Back to News
Market Impact: 0.22

Everyone's Nervous About GitLab. That's Exactly Why You Should Buy It!

GTLBUBSNVDAINTCNFLX
Analyst InsightsCompany FundamentalsCorporate Guidance & OutlookArtificial IntelligenceTechnology & InnovationInvestor Sentiment & Positioning

GitLab is trading at about 3x forward price-to-sales, or roughly 2x forward EV/sales, despite nearly 90% gross margins, expected revenue growth of 15% to 17% this year, and strong free cash flow. The article argues the stock is overly punished by AI-disruption fears, citing stable customers, high retention, and a large on-premises, regulated customer base that should reduce disruption risk. UBS initiated at neutral and Guggenheim downgraded to neutral, but the piece frames the valuation as too cheap relative to its fundamentals.

Analysis

The market is treating GTLB like a structural loser from AI, but the more important signal is that the selloff has pushed the stock into a valuation regime that implies either outright growth decay or a major margin reset. That looks disconnected from the customer mix: regulated enterprises and public sector buyers tend to adopt platform changes slowly, which means the revenue base should be more resilient than AI-disruption narratives suggest. In other words, the bear case is being priced as if customer churn will reaccelerate immediately, when the real risk is a longer-duration multiple compression rather than a near-term fundamental break. The second-order effect is that GTLB’s AI exposure may be more incremental than existential. If Duo and consumption attach rates work, AI becomes a monetization lever layered onto an already sticky workflow, not a replacement threat; that matters because the market is valuing the company as though AI is purely destructive. The balance sheet also gives management optionality to defend growth with go-to-market investment without needing to sacrifice profitability, which should limit downside if execution remains steady over the next 2-3 quarters. The main risk is not product obsolescence, but a prolonged proof cycle: if billings and NRR do not inflect, the stock can stay cheap for months even if the thesis is intact. Conversely, any upward revisions to FY growth or evidence that AI attach is expanding seat expansion/consumption should force a rapid multiple re-rating because the stock is already trading at SaaS-distress levels. UBS-style neutralization of the name may itself be the catalyst for a contrarian squeeze once the market stops treating the narrative as binary. Net: this is a valuation dislocation more than a fundamentals collapse, and the asymmetry favors owning optionality ahead of a sentiment reset rather than waiting for perfect confirmation.